Towards Healthcare
DNA Damaging Agents Market to Lead USD 46.31 Bn by 2034

DNA Damaging Agents Market Surges with Radiotherapy

According to market projections, the DNA damaging agents sector is expected to grow from USD 15.33 billion in 2024 to USD 46.31 billion by 2034, reflecting a CAGR of 11.67%. Ongoing developments in the cancer domain are impacting the global market expansion. North America led the market due to a rise in cancer cases.

Content

  • Last Updated: 20 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Kesiya Chacko is an accomplished market research professional with over 4+ years of experience in the healthcare industry, known for delivering actionable insights and strategic analysis that empower healthcare organizations to navigate complex, rapidly evolving markets.

Kesiya began her research career with Precedence Research, where she built a strong foundation in pharmaceutical and healthcare market analysis. Today, she plays an integral role at Towards Healthcare, contributing to in-depth, client-centric research initiatives. She also brings her expertise to Statifacts, supporting broader research functions with a focus on cross-sector healthcare trends and data interpretation.

Her commitment to high-quality analysis, combined with a strong grasp of regulatory and market dynamics, makes her a trusted contributor to healthcare firms seeking future-ready, data-backed decisions. Kesiya’s work spans the analysis of industry trends, competitive benchmarking, and evaluation of regulatory and innovation-driven shifts.

Talk to us
FAQ's

The DNA damaging agents market stands at USD 17.12 billion in 2025 and is expected to reach USD 46.31 billion by 2034, growing at a CAGR of 11.67% from 2024 to 2034.

North America is currently leading the DNA damaging agents market share by 40% due to the rising cancer cases and R&D investments.

Some key players include Roche,Genentech, Bristol-Myers Squibb, AstraZeneca, Pfizer, and Novartis.

Platinum-based drugs, PARP inhibitors, antimetabolites, and topoisomerase poisons are widely used in ovarian cancer.

US FDA, NIH, CDC, NCI, NCBI, EPA, EMA, IARC, ACTREC, MedlinePlus.gov, ClinicalTrials.gov.
Any Questions